On Monday shares of Flextronics International Ltd. (NASDAQ:FLEX) closed at $12.03. Company’s sales growth for last 5 years was -3.30% and EPS growth for next 5 years is recorded as 13.00%. It was reported on 1 May, that Flextronics International Ltd. (NASDAQ:FLEX) is set to buy Mirror Controls International from Dutch private equity firm Egeria for $508 million.
Titan International Inc. (NYSE:TWI) in last trading activity moved up 5.19% to close at $11.96. Company weekly performance is 25.76% while its quarterly performance stands at 27.85%. Titan International Inc. (NYSE:TWI) is -31.66% away from its 52 week high. On 30 April, Titan International, Inc. (NYSE: TWI) announced that first quarter revenue and performance results. Sales for the first quarter of 2015 were $402.1 million down 25.4 percent, compared to $538.9 million in the first quarter of 2014. Gross profit for the first quarter of 2015 was $42.8 million, or 10.6 percent of net sales, compared to $54.6 million, or 10.1 percent of net sales for the first quarter of 2014.
On last trading day Altria Group Inc. (NYSE:MO) moved up 0.04% to close at $50.68. Its volatility for the week is 1.40% while volatility for the month is 1.47%. MO’s sales growth for past 5 years was 0.80% and its EPS growth for past 5 years was 10.70%. Altria Group Inc. (NYSE:MO) monthly performance is -1.00%. Altria Group Inc. (NYSE:MO) was upgraded by analysts at Vetr
from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
On Monday shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) closed at $15.69. Company’s sales growth for last 5 years was 40.60%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) on April 20, 2015, shared highlights of new data it presented at the American Association for Cancer Research (AACR) annual meeting. Halozyme also announced plans to present interim results of its randomized Phase 2 study in pancreatic cancer, Study 202, next month at the annual meeting of the American Society of Clinical Oncology (ASCO).
On last trading day Theravance Inc. (NASDAQ:THRX) decreased -1.05% to close at $16.45. Its volatility for the week is 6.03% while volatility for the month is 5.14%. THRX’s sales growth for past 5 years was -19.20% and its EPS growth for past 5 years was 13.30%. Theravance Inc. (NASDAQ:THRX) monthly performance is 8.40%. On 1 May, GlaxoSmithKline plc and Theravance, Inc (NASDAQ:THRX) have announced that their drug Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]) has been approved by the US Food and Drug Administration (FDA) as a once-daily treatment of asthma in patients aged 18 years and older.